Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

Most patients with acute myeloid leukemia (AML) develop refractory/relapsed (R/R) disease
even in the presence of novel and targeted therapies. Given the biological complexity of the …

SHP2 (PTPN11) acts upstream of SOS1/2 to enable RAS activation. Allosteric SHP2
inhibitors (SHP2i) in the clinic prevent SHP2 activation, block proliferation of RTK-or cycling …

Patients with FLT3-mutated AML have a high relapse rate and suboptimal outcomes. Many
have co-mutations suitable for measurable residual disease (MRD) monitoring by RT-qPCR …

The clinical development of tyrosine kinase inhibitors (TKI) has led to great strides in
improving the survival of chronic myeloid leukemia (CML) and acute myeloid leukemia …

Simple Summary Treatment of acute myeloid leukemia continues to progress. Although a
number of therapies are efficacious in treating acute myeloid leukemia, some are intolerable …

FMS-like tyrosine kinase 3 (FLT3) is mutated in approximately 30% of acute myeloid
leukemia (AML) patients. The presence of FLT3-ITD (internal tandem duplication, 20–25%) …

Background Patients with relapsed or refractory acute myeloid leukemia (R/R AML) and
FLT3‐internal tandem duplication (FLT3‐ITD) respond infrequently to salvage …

The traditionally dismal outcome of acute myeloid leukemia (AML) patients carrying the FMS-
related tyrosine kinase 3 (FLT3) mutations has been mitigated by the recent introduction of …

FMS-related tyrosine kinase 3 (FLT3) mutations, present in about 25%-30% of acute myeloid
leukemia (AML) patients, constitute one of the most frequently detected mutations in these …